Infliximab

LCD Information Document Information Source LCD ID N/A LCD ID L35677 Original ICD-9 LCD ID Not Applicable LCD Title Infliximab Proposed LCD in Comment Period N/A Source Proposed LCD DL35677 Opens in a new window Original Effective Date For services performed on or after 10/01/2015 Revision Effective Date For services performed on or after 08/08/2024 Revision Ending Date N/A Retirement Date N/A Notice Period Start Date 12/22/2016 Notice Period End Date 02/05/2017 CPT codes, descriptions, and other data only are copyright 2025 American Medical Association. All Rights Reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. CPT is a registered trademark of the American Medical Association. Current Dental Terminology © 2025 American Dental Association. All rights reserved. Copyright © 2026, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at ub04@aha.org or 312‐422‐3366. Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates. Issue Issue Description This LCD outlines limited coverage for this service with specific details under Coverage Indications, Limitations and/or Medical Necessity. Issue - Explanation of Change Between Proposed LCD and Final LCD CMS National Coverage Policy Title XVIII of the Social Security Act 1862(a)(1)(A) allows coverage and payment for only those services that are considered to be medically reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member. CMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 1, §30 Drugs and Biologicals, §30.1 Drugs Included in the Drug Compendia, §30.2 Approval by Pharmacy and Drug Therapeutics Committee, §30.3 Combination Drugs, §30.4 Drugs Specially Ordered for Inpatients, §30.5 Drugs for Use Outside the HospitalCMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 15, §50 Drugs and Biologicals, §50.1 Definition of Drug or Biological, §50.4.1 Approved Use of Drug, §50.4.2 Unlabeled Use of Drug, §50.4.3 Examples of Not Reasonable and Necessary, §50.4.5 Off-Label Use of Drugs and Biologicals in an Anti-Cancer Chemotherapeutic Regimen Coverage Indications, Limitations, and/or Medical Necessity Infliximab is a chimeric monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFa) and blocks its activity. Overproduction of TNFa, which is a key inflammatory mediator, leads to inflammation in conditions such as Crohn’s disease, rheumatoid arthritis and other autoimmune diseases.The use of infliximab will be considered medically reasonable and necessary in the following circumstances: • To reduce the signs and symptoms and induce and maintain clinical remission in adult and pediatric patients with moderately to severely active Crohn’s disease in patients who have had an inadequate response to conventional therapy (e.g., corticosteroids, aminosalicylates, and immunosuppressive agents). • To reduce the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure for patients with fistulizing Crohn’s disease. Normally, the patient receives an infusion for this indication at weeks 0, 2 & 6. Subsequent treatments will be covered if the patient responds to the initial treatment as demonstrated by a reduction in signs and symptoms. • To reduce the signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function, in patients with psoriatic arthritis. Normally, the patient receives an infusion for this indication at weeks 0, 2 & 6. Subsequent treatments will be covered if the patient responds to the initial treatment as demonstrated by a reduction in signs and symptoms.• When used in combination with methotrexate, to reduce the signs and symptoms, inhibit the progression of structural damage and improve physical function in patients with moderately to severely active rheumatoid arthritis. Normally, the patient receives an infusion of infliximab for this indication at weeks 0, 2 & 6 and then approximately every 8 weeks.• To reduce the signs and symptoms in patients with active ankylosing spondylitis. Normally the patient receives an infusion for this indication at 0, 2 & 6 weeks. Subsequent treatment will be covered if the patient responds to the initial treatment as demonstrated by a reduction in signs and symptoms.• For the treatment of adult patients with chronic severe plaque psoriasis (as evidenced by plaques covering at least 10% of the body surface) who have failed prior treatment with psoralen-ultraviolet A (UVA), or ultraviolet B (UVB) light therapy; or are candidates for systemic therapy when other conventional systemic therapies have failed (methotrexate, cyclosporine, Soriatane®); or the patient has contraindications to these treatments. Infliximab should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician. Normally the patient receives an infusion at 0, 2 & 6 weeks and every 8 weeks thereafter.• To reduce signs and symptoms, achieve clinical remission and mucosal healing, and eliminate corticosteroid use in patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, such as aminosalicylates, corticosteroids, or immunosuppressants (unless the patient is unable to tolerate these drugs). Normally, the patient receives an infusion for this indication at 0, 2 & 6 weeks, and then every 8 weeks thereafter.• As an off-label use for reactive arthritis and inflammatory bowel disease (e.g., Reiter’s Syndrome who have failed or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate and sulfasalazine).• As an off-label use for hidradenitis suppurativa in the treatment of persons with severe disease refractory to systemic antibiotics and surgical treatments. • As an off-label use for Behçet’s Disease (BD), also known as Behçet’s Syndrome, in patients without an adequate response to initial therapy, for the treatment of clinical manifestations of BD such as severe ocular involvement, major organ involvement, severe gastrointestinal or neurological involvement and resistant cases of joint or mucocutaneous involvement (i.e., painful oral and genital ulcers).• As an off-label use for patients with chronic pulmonary sarcoidosis who remain symptomatic despite treatment for 3 or more months with steroids (10 mg per day or more) and immunosuppressants (such as azathioprine, cyclophosphamide or methotrexate) or have a contraindication or intolerance to 1 immunosuppressant (such as azathioprine, cyclophosphamide, or methotrexate) and the patient is not receiving infliximab in combination with either of the following: 1) Biologic disease-modifying anti-rheumatic drugs (DMARDs) [e.g., Enbrel® (etanercept), Humira® (adalimumab), Cimzia® (certolizumab), Simponi® (golimumab)] 2) Janus kinase inhibitor [e.g., Xeljanz® (tofacitinib)]. The current and prospective roles of infliximab in the treatment of pulmonary sarcoidosis do not currently have Food and Drug Administration (FDA) approval; therefore, it is recommended that providers consult the literature for proper dosing of infliximab. Note: For patients, who are unable to tolerate methotrexate or in the rare instance that methotrexate is contraindicated for a patient, treatment with infliximab alone will be covered only if documentation is maintained in the patient’s record that clearly indicates the reason that the patient cannot take methotrexate.Infliximab will only be covered for the above indications when no contraindications to its use exist including: a. Class III or IV congestive heart failure; or b. Untreated active or latent tuberculosis LIMITATIONS When used in combination with other biologics, such as Enbrel®(etanercept), Kineret® (anakinra), Orencia®(abatacept), Rituxan®(rituximab), Humira®(adalimumab), Cimzia® (certolizumab), Simponi® (golimumab), or a Janus kinase inhibitor [e.g. Xeljanz® (tofacitinib)], infliximab is considered not medically reasonable and necessary and therefore, not covered. Summary of Evidence N/A Analysis of Evidence (Rationale for Determination) N/A

Infliximab is a chimeric monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFa) and blocks its activity. Overproduction of TNFa, which is a key inflammatory mediator, leads to inflammation in conditions such as Crohn’s disease, rheumatoid arthritis and other autoimmune diseases. The use of infliximab will be considered medically reasonable and necessary in the following circumstances: • To reduce the signs and symptoms and induce and maintain clinical remission in adult and pediatric patients with moderately to severely active Crohn’s disease in patients who have had an inadequate response to conventional therapy (e.g., corticosteroids, aminosalicylates, and immunosuppressive agents). • To reduce the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure for patients with fistulizing Crohn’s disease. Normally, the patient receives an infusion for this indication at weeks 0, 2 & 6. Subsequent treatments will be covered if the patient responds to the initial treatment as demonstrated by a reduction in signs and symptoms. • To reduce the signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function, in patients with psoriatic arthritis. Normally, the patient receives an infusion for this indication at weeks 0, 2 & 6. Subsequent treatments will be covered if the patient responds to the initial treatment as demonstrated by a reduction in signs and symptoms. • When used in combination with methotrexate, to reduce the signs and symptoms, inhibit the progression of structural damage and improve physical function in patients with moderately to severely active rheumatoid arthritis. Normally, the patient receives an infusion of infliximab for this indication at weeks 0, 2 & 6 and then approximately every 8 weeks. • To reduce the signs and symptoms in patients with active ankylosing spondylitis. Normally the patient receives an infusion for this indication at 0, 2 & 6 weeks. Subsequent treatment will be covered if the patient responds to the initial treatment as demonstrated by a reduction in signs and symptoms. • For the treatment of adult patients with chronic severe plaque psoriasis (as evidenced by plaques covering at least 10% of the body surface) who have failed prior treatment with psoralen-ultraviolet A (UVA), or ultraviolet B (UVB) light therapy; or are candidates for systemic therapy when other conventional systemic therapies have failed (methotrexate, cyclosporine, Soriatane ® ); or the patient has contraindications to these treatments. Infliximab should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician. Normally the patient receives an infusion at 0, 2 & 6 weeks and every 8 weeks thereafter. • To reduce signs and symptoms, achieve clinical remission and mucosal healing, and eliminate corticosteroid use in patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy, such as aminosalicylates, corticosteroids, or immunosuppressants (unless the patient is unable to tolerate these drugs). Normally, the patient receives an infusion for this indication at 0, 2 & 6 weeks, and then every 8 weeks thereafter. • As an off-label use for reactive arthritis and inflammatory bowel disease (e.g., Reiter’s Syndrome who have failed or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate and sulfasalazine). • As an off-label use for hidradenitis suppurativa in the treatment of persons with severe disease refractory to systemic antibiotics and surgical treatments. • As an off-label use for Behçet’s Disease (BD), also known as Behçet’s Syndrome, in patients without an adequate response to initial therapy, for the treatment of clinical manifestations of BD such as severe ocular involvement, major organ involvement, severe gastrointestinal or neurological involvement and resistant cases of joint or mucocutaneous involvement (i.e., painful oral and genital ulcers). • As an off-label use for patients with chronic pulmonary sarcoidosis who remain symptomatic despite treatment for 3 or more months with steroids (10 mg per day or more) and immunosuppressants (such as azathioprine, cyclophosphamide or methotrexate) or have a contraindication or intolerance to 1 immunosuppressant (such as azathioprine, cyclophosphamide, or methotrexate) and the patient is not receiving infliximab in combination with either of the following: 1) Biologic disease-modifying anti-rheumatic drugs (DMARDs) [e.g., Enbrel ® (etanercept), Humira ® (adalimumab), Cimzia ® (certolizumab), Simponi ® (golimumab)] 2) Janus kinase inhibitor [e.g., Xeljanz ® (tofacitinib)]. The current and prospective roles of infliximab in the treatment of pulmonary sarcoidosis do not currently have Food and Drug Administration (FDA) approval; therefore, it is recommended that providers consult the literature for proper dosing of infliximab. Note: For patients, who are unable to tolerate methotrexate or in the rare instance that methotrexate is contraindicated for a patient, treatment with infliximab alone will be covered only if documentation is maintained in the patient’s record that clearly indicates the reason that the patient cannot take methotrexate. Infliximab will only be covered for the above indications when no contraindications to its use exist including: a. Class III or IV congestive heart failure; or b. Untreated active or latent tuberculosis LIMITATIONS When used in combination with other biologics, such as Enbrel ® (etanercept), Kineret ® (anakinra), Orencia ® (abatacept), Rituxan ® (rituximab), Humira ® (adalimumab), Cimzia ® (certolizumab), Simponi ® (golimumab), or a Janus kinase inhibitor [e.g. Xeljanz ® (tofacitinib)], infliximab is considered not medically reasonable and necessary and therefore, not covered.